key: cord-1045755-ckimecz4
authors: Cereser, Lorenzo; Da Re, Jacopo; Zuiani, Chiara; Girometti, Rossano
title: Chest high-resolution computed tomography is associated to short-time progression to severe disease in patients with COVID-19 pneumonia
date: 2020-10-25
journal: Clin Imaging
DOI: 10.1016/j.clinimag.2020.10.037
sha: b98677cdc9ec7adee52869da4ee338c60e096a9c
doc_id: 1045755
cord_uid: ckimecz4

OBJECTIVE: In patients with mild COVID-19 pneumonia, chest high-resolution computed tomography (HRCT) is advised when risk factors for severe disease (i.e., age > 65 years and/or comorbidities) are present, and can influence management strategy. The objective was to assess whether HRCT is associated to short-time development of severe disease in patients with COVID-19 pneumonia. METHODS: Seventy-seven consecutive patients (mean age, 64 ± 15 years) with mild COVID-19 pneumonia (no or mild respiratory failure) that underwent HRCT were retrospectively identified. Fifty-two on 77 patients had reported risk factors for severe disease. A chest-imaging devoted radiologist recorded, on a per-examination basis, the following HRCT features: ground-glass opacity, crazy-paving pattern, consolidation, organizing pneumonia (OP) pattern, mosaic attenuation, and nodules. The extent of each feature (total feature score, TFS) was semi-quantitatively assessed. Total lung involvement (TLI) was defined as the sum of all TFSs. The study outcome was defined as the occurrence of severe disease (moderate-to-severe respiratory failure) within 15 days from HRCT. Logistic regression analysis was performed to assess if age, comorbidities, and HRCT features were associated to severe disease. RESULTS: On univariable analysis, severe disease was significantly associated with age > 59 years (29/47 patients, 61.7%) (p = 0.013), and not significantly associated with having comorbidities (22/44 patients, 50.0%). On multivariable analysis, TLI >15 and OP pattern >5 were independently associated to severe disease, with odds ratio of 8.380 (p = 0.003), and of 4.685 (p = 0.035), respectively. CONCLUSION: Short-time onset of severe COVID-19 was associated to TLI >15 and OP pattern score > 5. Severe disease was not associated to comorbidities.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the agent causing the SARS-CoV-2 disease (COVID-19) ongoing pandemic, responsible of a constantly growing number of infections and deaths worldwide [1] . Clinical presentation of COVID-19 is variable. While some patients are asymptomatic, the disease can manifest with symptoms such as fever, dry cough, and dyspnea, possibly progressing to respiratory failure requiring admission to intensive care unit (ICU) and death [2] .

To date, real-time reverse transcription-polymerase chain reaction (RT-PCR) of viral nucleic acid is regarded as the reference standard for COVID-19 diagnosis [3] . The peculiar COVID-19 pandemic contingency we are facing, along with possible constraints in having fast RT-PCR testing, has made high-resolution computed tomography (HRCT) a potentially valuable tool for helping referring physicians in the clinical decision making process. Radiologic societies worldwide released consensus statements and advice documents, in order to clarify the role of imaging in diagnosis and management of patients with suspected or diagnosed COVID-19 [4] [5] [6] [7] . In particular, in patients who show mild respiratory disease and RT-PCR positivity or moderate-to-high pre-test probability of COVID-19 in the absence of RT-PCR test, imaging is advised for age >65 years and comorbidities such as cardiovascular disease, diabetes mellitus, chronic respiratory By performing a computerized search, we identified all the consecutive adult patients with suspected COVID-19 who underwent chest HRCT examination in our COVID-19-center between March 08, 2020, and April 16, 2020 . The disease severity was classified according to the following criteria from the Italian Society of Emergency Medicine (SIMEU) [17] : (i) category I disease, including fever without respiratory failure and normal chest X-ray; (ii) category II disease, including fever with chest X-ray and arterial blood gas test indicating lung focus and/or mild respiratory failure (partial pressure of arterial blood oxygen

[PaO2] > 60 mmHg); (iii) category III disease, including fever with moderate-severe respiratory failure (PaO2 < 60 mmHg in room air); (iv) category IV disease, including respiratory failure with suspected initial acute respiratory distress syndrome (ARDS) or complicated pneumonia; and (v) category V disease, consisting of ARDS. Treatments included oxygen therapy and/or continuous positive airway pressure (CPAP) ventilation in patients with category III-IV disease, and orotracheal intubation with invasive ventilation in patients with category IV-V disease, respectively [17] .

Of 192 eligible subjects we excluded 104 patients with negative RT-PCR test for SARS-

Examinations were performed on a 64-row scanner (LightSpeed, General Electric, Milwaukee, Wisconsin, USA), with the patient in the supine position. The whole thorax was scanned volumetrically at suspended full inspiration, with acquisition parameters as follows: tube potential, 120 kV; tube current modulation range, 100-350 mA; gantry Two sets of images were reconstructed and displayed, namely a first set with high-spatialfrequency algorithm and pulmonary parenchyma windowing (level, −500 HU; width, 1700 HU), and a second set with soft tissue algorithm and windowing (level, 50 HU; width, 350 HU).

A radiologist with 10 years of experience in thoracic imaging reviewed all the chest HRCT examinations on a picture archiving and communication system workstation (Suitestensa Ebit srl, Esaote Group Company, Genoa, Italy), blinded to patients' clinical and laboratory data. On a per-examination basis, each lung was divided into three zones, as follows: upper zone (above the carina), middle zone (from the carina to the inferior pulmonary veins), and lower zone (below the inferior pulmonary veins), resulting in a total of 6 zones (3 per lung). The reader assessed the zonal extent of each of the over-mentioned six HRCT pulmonary features, scoring it semi-quantitatively as follows: score 0 if there was no involvement; score 1 in the case of < 25% involvement; score 2 for a ≥ 25% to < 50% involvement; score 3 for a ≥ 50% to < 75% involvement; score 4 for ≥ 75% involvement [15] . Therefore, the total score for each pulmonary feature (total feature score [TFS]) ranged 0-24. Total lung involvement (TLI) was defined as the sum of all TFSs. Presence of significant pleural effusion (> 3 cm) was also evaluated.

For all patients we recorded age, sex, presence of comorbidities (number and type), time from symptoms onset and HRCT examination, and SIMEU category as assigned by the referring physician (both at the time of HRCT, as well as the worst one observed in the 15 days following the examination). When not clearly reported by the referring physician, the SIMEU category was derived by the study coordinator, who was not involved in image analysis, and was unblinded to clinical data. This occurred in 26/77 patients at the time of HRCT, and 17/77 patients in the 15 days following HRCT.

For the purpose of analysis, we dichotomized SIMEU categories into two groups, namely:

(i) mild disease group, including patients with no or mild respiratory failure (SIMEU J o u r n a l P r e -p r o o f Journal Pre-proof category I or category II); (ii) severe disease group, including patients with moderate-tosevere respiratory failure or ARDS (SIMEU category III to V).

After checking for data normality with the Shapiro-Wilk test, we presented clinical data and HRCT features with mean ± standard deviation or median with the interquartile range (IQR). Proportions were coupled with 95% confidence intervals (95%CI) when relevant.

First, we performed a receiver-operating characteristic (ROC) analysis, using the Youden index to calculate the cut-off of TFS, TLI, and age better balancing sensitivity and specificity in assessing the study outcome. The latter was defined as the occurrence of severe disease in the 15 days following the examination, i.e. the shift from SIMEU category I-II at the time of HRCT to SIMEU category III-V. The area under the curve (AUC) was calculated as well.

Second, we run a logistic regression analysis with the stepwise approach to assess which of the clinical variables and HRCT features was associated as an independent predictor of the study outcome occurrence. The model included age, sex, number of comorbidities and

There is intense debate on the use of HRCT in COVID-19 pneumonia, given the variability in locally available resources, and need for avoiding secondary exposure of patients and healthcare professional in the Radiology Department [19, 20] . We found that short-term clinical evolution, i.e. a shift from mild disease (SIMEU category I-II) to severe disease (SIMEU category III-V) within 15 days from baseline HRCT, was significantly associated with the presence of an OP pattern score > 5, and a TLI score > 15. This association was also found in univariable analysis for patients aged >59 years.

In our series, about two third of patients mirrored the "clinical scenario 1" recently prompted by a Fleischner Society consensus document [6] , which recommends chest imaging when mild features consistent with COVID-19 pneumonia coexist with risk factors for severe disease (age > 65 years or at least one comorbidity). Our results reasonably validate that indication to HRCT in order to provide a baseline examination for future comparison, and intensify the monitoring of patients with imaging findings predictive for clinical worsening.

However, in accordance with Wei et al. [21] , we found no relationship between comorbidities and severe disease at multivariable analysis. This result is in contrast with previous Authors, who found comorbidities to predict several adverse outcomes [16, 22] , including admission to ICU and death [14] . The discrepancy might be related to confounding factors such as smoking status, and under-reporting of pre-existing pathologies impacting on COVID-19 outcomes [23]. This might also explain why about 50% of patients (16/33) with no comorbidities progressed to severe disease in our series.

Our results suggest that, in the current scenario in which it is difficult to assess the Of note, our model included comorbidities as a whole rather than individually. This choice was related to the low prevalence of each comorbidity in our series, except for cardiovascular ones (42%). We believe that further studies on larger populations should address whether different comorbidities can affect prognosis at a different degree.

Our results on TLI are in line with previous studies showing that the extent of lung involvement, defined as CT score [15] , CT severity score [16] , or, conversely, well aerated lung parenchyma [14] , is predictive of mortality, progression to severe disease, and ICU admission or death, respectively. This is reasonably related to the extensive diffuse alveolar damage (DAD) as the distinctive pathophysiological characteristic of the disease [24, 25] . As expected from still limited knowledge on COVID-19 pneumonia, our results are difficult to compare with previous ones, e.g. in terms of definition of severe disease, method for assessing lung involvement, and amount of involved lung parenchyma that predicts clinical progression. While software-based methods such as the one proposed by Colombi et al. [14] can expectedly provide reliable and repeatable quantitative assessment, TLI can reasonably be of help when software-based evaluation is unavailable, or provide more reproducible results than those of different software-based methods. Of note, J o u r n a l P r e -p r o o f 

COVID-19) in the EU/EEA and the UK -ninth update

Clinical Characteristics of Coronavirus Disease 2019 in China

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection

Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection

RCR position on the role of CT in patients suspected with COVID-19 infection

The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus

COVID-19): Role of Chest CT in Diagnosis and Management

CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China

Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients

Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

Computed Tomographic Features and Short-term Prognosis of Coronavirus Disease 2019 (COVID-19) Pneumonia: A Single-Center Study from Kashan, Iran. Radiology: Cardiothoracic Imaging

Well-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia

Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China

Early Prediction of Disease Progression in 2019 Novel Coronavirus Pneumonia Patients Outside Wuhan with CT and Clinical Characteristics. medRxiv

First Line Covid-19. Emergency Department Organizational Management within Epidemic or Pre-Epidemic Outbreak Areas

Organizing pneumonia: typical and atypical HRCT patterns

Integrated Radiologic Algorithm for COVID-19 Pandemic

Henry TS; six signatories. A role for CT in COVID-19? What data really tell us so far

Risk factors for severe COVID-19: Evidence from 167 hospitalized patients in Anhui

The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia

Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS)

Successful treatment of suspected organizing pneumonia in a patient with Middle East respiratory syndrome coronavirus infection: a case report

Histopathologic Changes and SARS-CoV-2

Immunostaining in the Lung of a Patient With COVID-19

Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan